<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-12-22">22 December 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">European</forename><forename type="middle">Adpkd</forename><surname>Forum</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Multispecialist</forename><surname>Roundtable</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tess</forename><surname>Harris</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">PKD International</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Richard</forename><surname>Sandford</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Academic Department of Medical Genetics</orgName>
								<orgName type="department" key="dep2">School of Clinical Medicine</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Brenda</forename><surname>De Coninck</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Dutch Kidney Patient Association (NVN)</orgName>
								<address>
									<addrLine>The Netherlands</addrLine>
									<settlement>Bussum</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Olivier</forename><surname>Devuyst</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Mechanisms of Inherited Kidney Disorders Group</orgName>
								<orgName type="department" key="dep2">Institute of Physiology</orgName>
								<orgName type="department" key="dep3">Zurich Center for Integrative Human Physiology</orgName>
								<orgName type="institution">University of Zurich</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joost</forename><forename type="middle">P H</forename><surname>Drenth</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="department" key="dep2">Medical Centre</orgName>
								<orgName type="institution">Radboud University</orgName>
								<address>
									<addrLine>The Netherlands</addrLine>
									<settlement>Nijmegen, Nijmegen</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tevfik</forename><surname>Ecder</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep2">Division of Nephrology</orgName>
								<orgName type="department" key="dep3">Faculty of Medicine</orgName>
								<orgName type="institution">Istanbul Bilim University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alastair</forename><surname>Kent</surname></persName>
							<affiliation key="aff6">
								<orgName type="laboratory">Genetics Alliance and Patients Network for Medical Research and Health (EGAN)</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ron</forename><forename type="middle">T</forename><surname>Gansevoort</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Nephrology</orgName>
								<orgName type="institution" key="instit1">University Medical Center Groningen</orgName>
								<orgName type="institution" key="instit2">University of Groningen</orgName>
								<address>
									<settlement>Groningen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jose</forename><surname>´luis Go ´rriz</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Department of Nephrology</orgName>
								<orgName type="department" key="dep2">Departamento de Medicina</orgName>
								<orgName type="institution" key="instit1">Hospital Clı ´nico Universitario</orgName>
								<orgName type="institution" key="instit2">INCLIVA</orgName>
								<orgName type="institution" key="instit3">Universitat de Vale `ncia</orgName>
								<address>
									<addrLine>Vale `ncia</addrLine>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Albert</forename><forename type="middle">C M</forename><surname>Ong</surname></persName>
							<affiliation key="aff9">
								<orgName type="laboratory">Academic Nephrology Unit</orgName>
								<orgName type="institution">University of Sheffield Medical School</orgName>
								<address>
									<settlement>Sheffield</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yves</forename><surname>Pirson</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Division of Nephrology</orgName>
								<orgName type="institution" key="instit1">Cliniques Universitaires Saint-Luc</orgName>
								<orgName type="institution" key="instit2">Universite ´catholique de Louvain</orgName>
								<address>
									<settlement>Brussels</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vicente</forename><forename type="middle">E</forename><surname>Torres</surname></persName>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Division of Nephrology and Hypertension</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Klemens</forename><surname>Budde</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Nephrology</orgName>
								<orgName type="laboratory">European Kidney Transplant Association (EKITA)</orgName>
								<orgName type="institution">Charite ´University</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Denis</forename><surname>Cle ´ment</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of the Dean</orgName>
								<orgName type="institution" key="instit1">European Society of Hypertension (ESH)</orgName>
								<orgName type="institution" key="instit2">Ghent University Hospital</orgName>
								<address>
									<settlement>Ghent</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lorenzo</forename><forename type="middle">E</forename><surname>Derchi</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Health Sciences -Radiology Section</orgName>
								<orgName type="laboratory">European Society of Radiology (ESR)</orgName>
								<orgName type="institution">University of Genoa</orgName>
								<address>
									<settlement>Genoa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marianna</forename><surname>Eleftheroudi</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Nephrology</orgName>
								<orgName type="laboratory">Formerly European Dialysis and Transplant Nurses Association/ European Renal Care Association (EDTNA-ERCA)</orgName>
								<orgName type="institution">&quot;Papageorgiou&quot; General Hospital</orgName>
								<address>
									<settlement>Thessaloniki</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elena</forename><surname>Levtchenko</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Pediatric Nephrology</orgName>
								<orgName type="laboratory" key="lab1">European Society of Paediatric Nephrology (ESPN)</orgName>
								<orgName type="laboratory" key="lab2">Leuven and Laboratory of Pediatrics</orgName>
								<orgName type="institution" key="instit1">University Hospitals Leuven</orgName>
								<orgName type="institution" key="instit2">KU Leuven</orgName>
								<address>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dorien</forename><surname>Peters</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Department of Human Genetics</orgName>
								<orgName type="laboratory">European Society of Human Genetics (ESHG)</orgName>
								<orgName type="institution">Leiden University Medical Center</orgName>
								<address>
									<addrLine>The Netherlands</addrLine>
									<settlement>Leiden</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hendrik</forename><surname>Van Poppel</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="laboratory">European Association of Urology (EAU)</orgName>
								<orgName type="institution">University Hospitals of KU Leuven</orgName>
								<address>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Raymond</forename><surname>Vanholder</surname></persName>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">Emeritus Professor of Nephrology</orgName>
								<orgName type="department" key="dep2">Department of Nephrology</orgName>
								<orgName type="institution">European Kidney Health Alliance (EKHA)</orgName>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="institution">University Hospital Ghent</orgName>
								<address>
									<settlement>Ghent</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-12-22">22 December 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">21CF718993CBA6E654CA5D4A56E26296</idno>
					<idno type="DOI">10.1093/ndt/gfx327</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:35+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterized by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations.</s><s>Individuals with ADPKD should have access to lifelong, multidisciplinary, specialist and patient-centred care involving: (i) a holistic and comprehensive assessment of the manifestations, complications, prognosis and impact of the disease (in physical, psychological and social terms) on the patient and their family; (ii) access to treatment to relieve symptoms, manage complications, preserve kidney function, lower the risk of cardiovascular disease and maintain quality of life; and (iii) information and support to help patients and their families act as fully informed and</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>active partners in care, i.e. to maintain self-management approaches, deal with the impact of the condition and participate in decision-making regarding healthcare policies, services and research.</s><s>Building on discussions at an international roundtable of specialists and patient advocates involved in ADPKD care, this article sets out (i) the principles for a patient-centred, holistic approach to the organization and delivery of ADPKD care in practice, with a focus on multispecialist collaboration and shared-decision making, and (ii) the rationale and knowledge base for a route map for ADPKD care intended to help patients navigate the services available to them and to help stakeholders and decision-makers take practical steps to ensure that all patients with ADPKD can access the comprehensive multispecialist care to which they are entitled.</s><s>Further multispecialty collaboration is encouraged to design and implement these services, and to work with patient organizations to promote awareness building, education and research.</s></p><p><s>Keywords: ADPKD, CKD, clinical practice, multispecialist care, polycystic kidney disease</s></p><formula xml:id="formula_0">I N T R O D U C T I O N</formula><p><s>Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterized by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations <ref type="bibr" target="#b0">[1]</ref>.</s><s>The renal cystic disease progresses throughout life, causing complications that include pain, cyst infections, bleeding and abdominal distention due to massive kidney enlargement.</s><s>Kidney function may not be affected for many years, owing to compensatory renal mechanisms.</s><s>However, most patients eventually develop end-stage renal disease (ESRD), typically before the age of 60 years, and require renal replacement therapy (RRT) by kidney transplantation or dialysis <ref type="bibr" target="#b1">[2]</ref>.</s><s>ADPKD accounts for approximately 1 in 10 of all patients needing RRT, corresponding to approximately 50 000 people across Europe <ref type="bibr" target="#b2">[3]</ref>.</s><s>Cysts also develop in the liver in most patients <ref type="bibr" target="#b3">[4]</ref> and occur less commonly in the seminal vesicles, pancreas, arachnoid membrane and spinal meninges <ref type="bibr" target="#b0">[1]</ref>.</s><s>Patients with ADPKD are at increased risk of cardiovascular and cerebrovascular complications, including hypertension, cardiac valvular abnormalities and intracranial aneurysms <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b5">6]</ref>.</s><s>The lifelong physical and psychological effects of ADPKD can impair quality of life (QoL) and interfere with social functioning and work <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>.</s><s>These effects may be underappreciated by many physicians, including nephrologists, especially during the early stage of the disease <ref type="bibr" target="#b8">[9]</ref>.</s><s>Although ADPKD is typically diagnosed in adulthood, it may present in children (and even prenatally) and there have been calls for greater recognition of symptomatic paediatric disease to facilitate early diagnosis and appropriate care <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref>.</s></p><p><s>Approaches to ADPKD care vary between and within European countries, with no widely accepted, evidence-based practice guidelines.</s><s>A Kidney Disease: Improving Global Outcomes (KDIGO) initiative has begun the process toward international guidelines by assessing the current state of knowledge and best practice and proposing a research agenda <ref type="bibr" target="#b0">[1]</ref>.</s></p><p><s>National guidelines have been developed in some countries <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15]</ref>, while European-level guidelines have been developed specifically regarding the therapeutic use of vasopressin V2 receptor antagonists <ref type="bibr" target="#b15">[16]</ref>.</s><s>Relatively little attention has been paid to the organization and delivery of ADPKD care and the means of overcoming barriers to the implementation of guidelines and patientcentred services.</s><s>Practice patterns for ADPKD care are not welldocumented across Europe.</s><s>Many patients may not have coordinated access to the necessary range of specialists with expertise in ADPKD and to patient-centred, multidisciplinary care.</s><s>Where specialized ADPKD centres exist, their roles, responsibilities and added value may be unclear among nephrologists in the local region.</s><s>Patients and carers may also lack a clear understanding of the available services and how to navigate these optimally.</s></p><p><s>In 2015, the European ADPKD Forum (EAF) published policy-focused recommendations to help address unmet needs among patients with ADPKD <ref type="bibr" target="#b16">[17]</ref>.</s><s>These included the development of nationally coordinated approaches to ADPKD care and efforts to empower patients and carers.</s><s>Such approaches require collaboration between all stakeholders.</s><s>Building on discussions at a roundtable of clinical specialists and patient advocates, convened by the EAF, this article sets out (i) the principles for a holistic, patient-centred approach to the organization and delivery of ADPKD care in practice, with a focus on multispecialist collaboration and shared-decision making and (ii) the rationale and knowledge base for a route map for ADPKD care.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>P R I N C I P L E S O F A D P K D C A R E : A M U L T I S P E C I A L I S T , P A T I E N T -C E N T R E D A P P R O A C H</head><p><s>Individuals with ADPKD should have access to lifelong, multidisciplinary, specialist and patient-centred care involving: (i) a holistic and comprehensive assessment of the manifestations, complications, prognosis and impact of the disease (in physical, psychological and social terms) on the patient and their family; (ii) access to treatment to relieve symptoms, manage complications, preserve kidney function, lower the risk of cardiovascular disease and maintain QoL; and (iii) information and support to help patients and their families maintain recommended selfmanagement approaches and to deal with the impact of the condition <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b16">17]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient-centred approach</head><p><s>We define a 'patient-centred' approach to ADPKD as one in which patients and carers are empowered to act as fully informed and active partners in decision-making regarding their care and in healthcare policies, services and research directly or indirectly related to the disease <ref type="bibr" target="#b16">[17,</ref><ref type="bibr">18]</ref>.</s><s>This requires patients and carers to have access to accurate, up-to-date information about ADPKD, their own clinical data and the opportunity to participate in decision-making.</s><s>Survey evidence suggests the provision of written materials, and referrals to patient support groups, at the time of diagnosis are variable and suboptimal <ref type="bibr" target="#b18">[19]</ref>.</s><s>All stakeholders, including national governments and healthcare providers, should support efforts to better inform patients and families and, more widely, to include patient organizations within strategic decision-making.</s><s>Patients participated at the KDIGO Conference <ref type="bibr" target="#b0">[1]</ref> and an expanded consultation regarding research priorities is underway among advocacy groups (T.</s><s>Harris, personal communication).</s><s>Researchers in Australia have also elicited the perspectives of patients and carers concerning clinical practice guidelines for ADPKD <ref type="bibr" target="#b19">[20]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Multidisciplinary coordination</head><p><s>The complex and heterogeneous manifestations of ADPKD often necessitate access to specialized services.</s><s>In order to establish strategies to detect complications and prevent progression of kidney failure, specialist care should start as soon as possible after diagnosis, ideally when kidney function is not yet impaired and protective measures can be taken.</s><s>Some patients present with impaired renal function and require RRT soon after diagnosis, while others may have a low risk of progressing to ESRD.</s><s>In all these cases, specialist care should still be considered.</s></p><p><s>All patients with ADPKD should have access to a nephrologist knowledgeable about the diverse aspects of the disease <ref type="bibr" target="#b0">[1]</ref>, including the multi-organ involvement, psychological and psychosocial issues, genetics, pain management and current treatment options, in addition to the 'core' management of renal function and RRT.</s><s>Depending on local circumstances, referral to an adult or paediatric nephrologist with specialist ADPKD expertise may also be helpful in some cases for particular aspects of care according to the evolving best practice, such as prognostic assessment, kidney cyst infections <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22]</ref>, specific reno-protective pharmacotherapy <ref type="bibr" target="#b15">[16]</ref> and for clinical trials and other types of research.</s><s>Patients should also have access to care from a range of other clinical specialists (e.g.</s><s>hepatology, clinical genetics, neurosurgery and anaesthesiology or pain specialists) and healthcare professionals who also have specific expertise in ADPKD, according to clinical need in the event of other disease manifestations and complications (e.g.</s><s>liver cyst complications, intracranial aneurysms, lumbar pain; Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>They may also require treatment for other chronic diseases (e.g.</s><s>diabetes) based on a consensus among all practitioners involved.</s></p><p><s>How multidisciplinary care is managed depends on the local, regional and national organization and resourcing of services.</s><s>Where possible, a team approach with all specialties provided in one centre would be expected to benefit expert and patient networking, efficiency and patient outcomes <ref type="bibr" target="#b0">[1]</ref>.</s><s>Specialist centres also have a potential role in coordinating research efforts locally, nationally and internationally.</s><s>This is not realistic for all patients, but most university hospitals should be able to provide most of the services required.</s><s>Where this is the case, these services should be coordinated institutionally in a patient-centred manner.</s><s>Not all patients are routinely cared for at university hospitals, of course, and some local nephrologists may not be able to offer all services necessary or may not have access within their hospital to colleagues from other specialties with appropriate ADPKD expertise.</s><s>In these cases, managed coordination and networking of local, regional or national ADPKD specialist services, based on a common understanding of the multifaceted needs of patients and carers, is important to optimize care and to benefit research.</s><s>Informal referral pathways often exist, but we argue that services should ideally be formally organized according to predefined pathways.</s><s>Such coordination requires a consensus involving all practitioners, patients and providers.</s></p><p><s>To our knowledge, the relative cost-effectiveness of different delivery models of multidisciplinary ADPKD care have not been compared.</s><s>Ongoing evaluation of the cost-benefit of care models is important, taking account of the 'downstream' increase in healthcare costs that occurs in later life among patients who require dialysis <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b23">24]</ref>.</s><s>However, managed coordination would be expected to facilitate prompt, accurate diagnosis, avoidance of duplication of tests, better management European ADPKD forum position statement of disease complications and manifestations, and evidencebased access to specific reno-protective treatment, and ultimately to improve patient outcomes.</s></p><p><s>New technologies could facilitate interdisciplinary networking and research, and promote patient empowerment and selfcare.</s><s>These include telecommunication and information technologies ('telemedicine' or 'telenephrology') that allow online consultation and videoconferencing, data and image sharing, education and biomarker development.</s><s>Such modalities could have a particular role in supporting consultation between local nephrology services and distant specialist centres on specific aspects of care and research, reducing the need for patients to travel to the latter.</s><s>These measures will be facilitated by the recent implementation of the European Rare Kidney Disease Reference Network (ERKNet), which aims to improve standards of diagnosis and treatment for rare and complex kidney diseases <ref type="bibr" target="#b24">[25]</ref>.</s><s>Polycystic liver disease will also be covered within the European Reference Network (ERN) on Hepatological Diseases (ERN RARE-LIVER) <ref type="bibr" target="#b25">[26]</ref>.</s></p><p><s>Patients' access to information also underpins their participation in shared decision-making.</s><s>Regular monitoring may be important for some patients to improve their understanding and sense of control, to facilitate self-management and to allow them to prepare for RRT <ref type="bibr" target="#b19">[20]</ref>.</s><s>For example, the Renal PatientView system in the UK (https://www.patientview.org/#/;</s><s>15 November 2017, date last accessed) provides patients with web-based access to laboratory results and educational material <ref type="bibr" target="#b26">[27,</ref><ref type="bibr" target="#b27">28]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A D P K D R O U T E M A P : C O N C E P T A N D A I M S</head><p><s>Route maps provide 'signposts' to health and social care for patients and their families in order to improve their access to information and to facilitate earlier diagnosis and improved care and support.</s><s>Route maps can also help health and social care professionals to communicate, and work in partnership, with patients and families.</s><s>Examples of route maps include those for arthritis <ref type="bibr" target="#b28">[29]</ref> and spinal muscular atrophy <ref type="bibr">[30]</ref>.</s></p><p><s>An ADPKD Patient Route Map is in development to promote good practice in lifetime ADPKD care among all stakeholders.</s><s>Specifically, the Route Map aims to:</s></p><p><s>• Inform patients and families about what they can expect from a good-quality service, engaging and supporting them to take a partnership role in their own care, thereby improving the dialogue between patients and physicians and helping patients to navigate available services • Assist patient organizations in participating in the decision-making regarding the design, implementation and assessment of ADPKD services • Support healthcare providers and policymakers to design, adapt or assess coordinated services to efficiently address current unmet needs and to take advantage of developments in knowledge, therapy and technology, taking into account local healthcare system conditions</s></p><p><s>The Route Map is being developed collaboratively by the EAF and PKD International, with input from member patient organizations across Europe.</s><s>It is not a clinical practice guideline and is not intended to be prescriptive, nor a complete solution appropriate for all settings.</s><s>Rather, it is intended to offer a practical, flexible, interactive and adaptable model that integrates, translates and stages key elements of good practice for patients and other stakeholders, according to the principles defined above and based on the latest knowledge base and good practice.</s><s>It will be published as an open-access resource on the PKD International website for use and local adaptation by all stakeholders (e.g.</s><s>patients, families, healthcare professionals and policymakers).</s></p><p><s>The Route Map is presented in terms of key assessments and interventions at distinct stages, together with considerations that apply to the different stages of the disease throughout a patient's lifetime (Figure <ref type="figure" target="#fig_1">2</ref>).</s><s>The following sections overview the main domains, highlighting key unmet needs and barriers and focusing on opportunities for inter-specialist co-operation for non-renal manifestations and complications.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S C R E E N I N G A N D D I A G N O S I S</head><p><s>A diagnosis of ADPKD can have important lifelong effects on patients, including psychosocial and financial consequences.</s><s>The advantages and disadvantages of offering screening to a patient's family members should be carefully discussed.</s><s>The offer of screening should be provided with appropriate counselling on the implications of a diagnosis for adults and children.</s><s>Routine presymptomatic screening of ADPKD is not recommended for atrisk children, while it is usually thought that the benefits outweigh the risks in adults <ref type="bibr" target="#b0">[1]</ref>.</s><s>Ultrasound imaging is recommended for parents of children or adolescents in whom ADPKD is suspected and who have no previous family history of ADPKD <ref type="bibr" target="#b12">[13]</ref>.</s></p><p><s>ADPKD is diagnosed in adults and children mainly by ultrasound imaging <ref type="bibr" target="#b0">[1]</ref>.</s><s>Magnetic resonance imaging (MRI) may be useful to confirm or exclude the diagnosis.</s><s>Both can be used for prognostic assessment.</s><s>Specialist consultation is recommended for paediatric patients with renal cysts, as genetic testing is often required to confirm the diagnosis when clinical findings are equivocal <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b12">13]</ref>.</s><s>A detailed examination and additional investigations should be performed to identify extra-renal manifestations if appropriate.</s></p><formula xml:id="formula_1">B L O O D P R E S S U R E C O N T R O L , L I F E S T Y L E A N D S E L F -C A R E</formula><p><s>Control of hypertension and other cardiovascular risk factors is a key aspect of early ADPKD management <ref type="bibr" target="#b0">[1]</ref>.</s><s>Cardiovascular disease is the leading cause of premature death in people with ADPKD <ref type="bibr" target="#b2">[3]</ref> and yet risk management may be sub-optimal <ref type="bibr" target="#b29">[31]</ref>.</s><s>Up to 20% of paediatric patients with ADPKD may have hypertension <ref type="bibr" target="#b30">[32]</ref>.</s><s>In children and adults, 24-h ambulatory blood pressure monitoring can be helpful to detect prehypertension and any diminution of the normal fall in overnight blood pressure <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b12">13]</ref>.</s></p><p><s>Patients should be provided with comprehensive, up-to-date written information on recommended lifestyle and self-care aspects (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Although evidence specifically in ADPKD is lacking, patients should be advised on the expected antihypertensive benefits of lifestyle adaptation, such as weight control, exercise and a low-salt diet.</s><s>There is no good evidence that proteinlimited diets slow the progression of ADPKD <ref type="bibr" target="#b31">[33]</ref>.</s><s>Others have advised a moderate protein intake (0.75-1.0 g/kg/day) for adults with ADPKD, commensurate with that in the general population <ref type="bibr" target="#b32">[34]</ref>.</s><s>KDIGO guidelines for general chronic kidney disease (CKD) care in adults recommend moderate protein limitation (to 0.8 g/kg/day) when estimated glomerular filtration rate (eGFR) is &lt;30 mL/min/1.73</s><s>m 2 , along with the avoidance of high protein intake (&gt;1.3 g/kg/day) in those at risk of CKD progression <ref type="bibr" target="#b33">[35]</ref>.</s><s>Where protein restriction is applied, it should preferably involve education by a renal dietician and monitoring for malnutrition, especially those patients with high total kidney and liver volumes whose nutritional intake may become insufficient.</s><s>A recent Cochrane review has drawn attention to the limitations in the evidence base for dietary interventions for adults with CKD <ref type="bibr" target="#b34">[36]</ref>.</s></p><p><s>Peer-to-peer support from patient organizations may aid adherence to lifestyle and diet measures, together with regular reinforcement by healthcare practitioners.</s></p><p><s>Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are the first-line antihypertensives in ADPKD.</s><s>The KDIGO CKD blood pressure target of 140/90 mmHg is recommended for individualized use, taking comorbidities into account <ref type="bibr" target="#b0">[1]</ref>.</s><s>Data from the HALT PKD study suggest that a lower target might benefit young hypertensive ADPKD patients (15-49 years) at CKD Stages 1 or 2 and without diabetes mellitus or significant cardiovascular comorbidities <ref type="bibr" target="#b35">[37]</ref>.</s><s>In this group, a target of 95/60-110/75 mmHg was associated with a slower increase in total kidney volume (TKV), though no overall change in the eGFR, together with a greater decline in the left-ventricular-mass index and a greater reduction in urinary albumin excretion, as compared with a target of 120/70-130/80 mmHg <ref type="bibr" target="#b35">[37]</ref>.</s><s>A cardiology referral is needed if signs or symptoms of cardiac disease are evident.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>L I V E R C Y S T S</head><p><s>Liver cysts are the most common extra-renal manifestation of ADPKD and a recent case series suggested that biliary disease is also a frequent complication in ADPKD <ref type="bibr" target="#b36">[38]</ref>.</s><s>Liver cysts can occur at any disease stage (irrespective of marked progression of CKD) and affect women in particular.</s><s>Liver cysts can contribute significantly to pain, gastrointestinal symptoms and QoL impairment <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b37">[39]</ref><ref type="bibr" target="#b38">[40]</ref><ref type="bibr" target="#b39">[41]</ref>.</s><s>All patients with ADPKD should be assessed for polycystic liver disease, and those with liver cyst complications should be referred to a hepatologist as necessary.</s><s>Liver symptoms can be assessed using the polycystic liver disease questionnaire (PLD-Q) <ref type="bibr" target="#b38">[40]</ref>.</s><s>Current guidelines suggest that patients with moderate-to-severe polycystic liver disease should avoid oestrogens <ref type="bibr" target="#b41">[42]</ref>, in view of the evidence that exogenous oestrogen increases liver (but not renal) volume in postmenopausal ADPKD patients <ref type="bibr" target="#b42">[43]</ref>.</s></p><formula xml:id="formula_2">I N T R A C R A N I A L A N E U R Y S M S</formula><p><s>Intracranial aneurysms are an uncommon but important manifestation of particular concern to patients.</s><s>One survey in patients with ADPKD found a self-reported prevalence rate of 5.0% for brain aneurysm and 7.5% for stroke or cerebral bleeding <ref type="bibr" target="#b5">[6]</ref>.</s><s>A recent systematic review reported that unruptured intracranial aneurysms occur in around 11% patients with <ref type="bibr" target="#b43">[44]</ref>, as compared with around 3% in the general population <ref type="bibr" target="#b44">[45]</ref>.</s><s>The rate of rupture among patients with ADPKD appears similar to that in the general population: a rupture rate of 0.4%/patient-year was reported among ADPKD patients with conservatively treated aneurysms <ref type="bibr" target="#b43">[44]</ref>.</s><s>In the general population, the rupture rate depends strongly on the size and location of the aneurysm.</s></p><p><s>Systematic screening for intracranial aneurysms is not recommended for all patients with ADPKD, but is recommended in certain groups at elevated risk <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b45">46]</ref>.</s><s>Consultation with a neurosurgeon and neurovascular radiologist is needed in the management of identified aneurysms <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b45">46]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>P A I N</head><p><s>Pain is a principal symptom of ADPKD.</s><s>Even in early disease stages, patients can experience acute or chronic pain that can interfere with daily activities and cause distress <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b46">47]</ref>.</s><s>ADPKD-specific causes of pain include kidney and liver cyst haemorrhage and infection and urinary stones.</s><s>Pain may be under-assessed in the clinic and under-recognized by physicians, leading to inadequate management and feelings of powerlessness among patients <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b46">47]</ref>.</s></p><p><s>Physicians should carefully ascertain and assess patients' pain at each clinic visit and discuss management options according to current best practice.</s><s>Chronic pain in ADPKD is often refractory, and may necessitate referral, e.g.</s><s>involving radiologists, physical therapists and pain specialists <ref type="bibr" target="#b0">[1]</ref>.</s><s>A multidisciplinary, stepwise protocol in the Netherlands has recently shown promising results <ref type="bibr" target="#b47">[48]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>P S Y C H O S O C I A L S U P P O R T</head><p><s>ADPKD can significantly impair QoL and psychosocial wellbeing, and can be associated with depression and anxiety <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b48">49]</ref>.</s><s>Typical issues include worry and fear (associated, for example with pain, unpredictability of symptoms, the effect of the disease on work and finances, future need for dialysis or the diagnosis of intracranial aneurysm), confusion (which might be linked with a lack of correct information), as well as anger and guilt.</s></p><p><s>Physicians should recognize the potential psychological, social and functional effects of ADPKD at all disease stages.</s><s>Measurement of patient-reported outcomes, such as healthrelated QoL, is important.</s><s>ADPKD-specific instruments are more sensitive than generic ones, especially in early disease.</s><s>Recently developed disease-specific tools include the ADPKD Genetic Psychosocial Risk Instrument (GPRI-ADPKD) <ref type="bibr" target="#b9">[10]</ref> and the ADPKD Impact Scale (ADPKD-IS) <ref type="bibr" target="#b49">[50]</ref>, along with the aforementioned PLD-Q <ref type="bibr" target="#b38">[40]</ref>.</s><s>Ideally, patient-reported outcomes should be measured routinely during consultations, although further research is required to define clinically significant changes in scores.</s><s>The UK Renal Registry is evaluating routine QoL data collection within its Transforming Participation in Chronic Kidney Disease initiative, which aims to help patients manage their own condition and plan future services <ref type="bibr" target="#b50">[51]</ref>.</s><s>The collection of patient-reported outcomes is also a potential role for reference networks at national and European levels.</s></p><p><s>Patients and carers should have access to psychological and social support services, according to need.</s><s>Patients and carers should also receive information on managing the impact of ADPKD on employment, mortgages and other financial aspects, and health insurance.</s><s>Patient organizations play an important role in this respect.</s><s>Other relevant educational topics for patients and parents include contraception, pregnancy and medication adverse effects <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b19">20]</ref>.</s><s>The role of complementary medicines is a topic of interest to some patients <ref type="bibr" target="#b19">[20]</ref> and on which nephrologists and other healthcare professionals may need to offer advice.</s><s>There is no evidence that any complementary or alternative therapy helps to protect the kidneys or to slow the progression of ADPKD.</s><s>Patients should be encouraged to ask their doctor before using any complementary therapy and should never stop a treatment prescribed by a doctor on the advice of a complementary practitioner without discussing it with their doctor.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>P R O G N O S T I C A S S E S S M E N T</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Progression risk scoring</head><p><s>Prognostic assessment during the early stages of ADPKD has become increasingly important to identify patients with rapidly progressing disease who may be eligible for new renoprotective therapies or clinical trials <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b51">52]</ref>.</s><s>It warrants associated investment, awareness building and training and support by healthcare policymakers and providers <ref type="bibr" target="#b16">[17]</ref>.</s></p><p><s>The height-adjusted TKV is the gold-standard image biomarker for early ADPKD progression <ref type="bibr" target="#b52">[53]</ref>.</s><s>Classical volumetry to measure TKV from MRI images is laborious and expensive and may not be viewed as an efficient use of time by some radiologists.</s><s>New, automated methods should allow faster, less labour-intensive imaging at lower costs and thereby facilitate repeat TKV measurement in routine practice <ref type="bibr" target="#b53">[54,</ref><ref type="bibr" target="#b54">55]</ref>.</s><s>In addition, estimating TKV using MRI images and the ellipsoid equation is an easy to use and quick surrogate for classical TKV measurement, and seems to perform sufficiently well to be used in clinical practice <ref type="bibr" target="#b55">[56]</ref>.</s><s>Improving the uptake and implementation of such methods, and access to repeat MRI imaging, should be a target for collaboration between nephrologists and radiologists.</s><s>An image classification of ADPKD based on heightadjusted TKV and age has been proposed to optimize patient selection for enrolment into clinical trials or treatment <ref type="bibr" target="#b56">[57]</ref>.</s><s>Other approaches to prognostic risk scoring include the PROPKD score, which predicts the risk of progression to ESRD using four factors: gender, presence of hypertension before 35 years of age, first urologic event before 35 years of age and genotype <ref type="bibr" target="#b57">[58]</ref>.</s><s>A recent study has demonstrated the prognostic value of fasting urine osmolality (Uosm) to predict disease progression and response to treatment in ADPKD <ref type="bibr" target="#b58">[59]</ref>.</s><s>Determination of Uosm is non-invasive, affordable and valued as an integrative marker of renal function that could improve or complement the existing scores to predict renal outcome in patients with ADPKD.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Genetic testing</head><p><s>Although diagnostic genetic testing for ADPKD mutations is not required for most patients, it can be important where clinical findings are equivocal or atypical, especially in children <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b12">13]</ref>.</s><s>Where possible, patients should have access to testing via clinical geneticists with ADPKD expertise.</s><s>Access to genetic testing varies across Europe with key barriers including the cost of tests, resourcing of services, diverse reimbursement policies and a lack of clear, reliable information in some countries.</s><s>Although data are lacking, the European Expert Group on Rare Diseases (EUCERD) have observed that genetic testing may offer economic advantages by avoiding unnecessary diagnostic and therapeutic procedures <ref type="bibr" target="#b59">[60]</ref>.</s><s>Next-generation sequencing technologies offer increasingly cost-efficient diagnostic strategies <ref type="bibr" target="#b60">[61]</ref>.</s><s>The ERKNet aims to develop standard criteria for genetic testing for inherited rare and complex kidney diseases <ref type="bibr" target="#b24">[25]</ref>.</s></p><p><s>Patients should have access to family planning services, including pre-implantation genetic diagnosis (PGD).</s><s>PGD is used in reproductive medicine to screen for DNA mutations that cause inherited diseases in embryos created by in vitro fertilization.</s><s>Anecdotally, PGD is of interest within the ADPKD patient community (T.</s><s>Harris, personal communication).</s><s>A UK survey suggested that many patients with ADPKD would seek PGD if it were available and that a majority believed it should be offered <ref type="bibr" target="#b62">[62]</ref>.</s><s>Currently, access to PGD varies for reasons that include regulatory, ethical and legal policies, cost, reimbursement policies, and attitudes among doctors and society <ref type="bibr" target="#b63">[63]</ref>.</s><s>Regarding cost issues, the potential for significant societal cost savings by avoiding ADPKD cases should be considered <ref type="bibr" target="#b0">[1]</ref>, although data are lacking.</s><s>Other barriers may include low awareness of the method among patients.</s><s>Nephrologists, geneticists and patient organizations have roles in collaboratively advocating for governments to formulate national polices on PGD.</s></p><p><s>All forms of genetic testing must be accompanied by access to accurate, personalized information and to counselling, preferably by clinical geneticists with ADPKD expertise <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b63">63]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S P E C I F I C R E N O -P R O T E C T I V E P H A R M A C O T H E R A P Y</head><p><s>In Europe, a vasopressin V2 receptor antagonist (tolvaptan) is indicated to slow the progression of cyst development and renal insufficiency in ADPKD in adults with CKD Stage 1-3 at initiation of treatment with evidence of rapidly progressing disease <ref type="bibr">[64]</ref>.</s><s>European experts have published a decision algorithm to assess whether treatment is warranted, taking into account the adverse event profile and costs of treatment <ref type="bibr" target="#b13">[14]</ref>.</s><s>This guidance is expected to also help set the indications for other future therapies.</s><s>Currently, patients' access to treatment, and its deployment within nephrology services, varies across Europe and national guidelines have been developed in some countries <ref type="bibr" target="#b64">[65,</ref><ref type="bibr" target="#b65">66]</ref>.</s><s>Shared decision-making with patients is advocated: issues to be discussed with patients include the mechanism of drug action, expected adverse events, and need for precautions and lifestyle modifications <ref type="bibr" target="#b15">[16]</ref>.</s><s>Due to its mode of action, tolvaptan causes class effects of thirst, polydipsia, dry mouth, nocturia, pollakisuria and polyuria.</s><s>Patients must be counselled to avoid dehydration <ref type="bibr">[64]</ref>.</s><s>In the TEMPO 3:4 trial, idiosyncratic increases [&gt;3Â the upper limit of normal (ULN)] in alanine transaminase (ALT) and aspartate transaminase (AST) were observed in 4.4% and 3.1% of tolvaptan-treated patients, respectively, compared with 1.0% and 0.8% of placebo recipients.</s><s>Two (0.2%) tolvaptan treated-patients, and a third patient treated in the TEMPO 4:4 extension trial, showed increases in hepatic enzymes (&gt;3Â ULN) with concomitant elevations in total bilirubin (&gt;2Â ULN) <ref type="bibr">[64,</ref><ref type="bibr" target="#b66">67]</ref>.</s><s>Blood testing for transaminases and bilirubin is therefore required prior to initiation of tolvaptan, continuing monthly for 18 months and at regular 3-monthly intervals thereafter <ref type="bibr">[64]</ref>.</s></p><p><s>Other novel pharmacological approaches to slowing ADPKD progression are currently under investigation <ref type="bibr" target="#b51">[52]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>F O L L O W -U P C A R E</head><p><s>Life-long follow-up care for patients with ADPKD requires coordination between nephrologists (locally and at specialist centres, where relevant), other secondary care specialists and primary care physicians.</s><s>Patients referred to specialist centres for particular assessments or interventions would typically be expected to return to the care of their local nephrologist for ongoing care, pending the need for any further consultation.</s><s>The frequency of scheduled nephrology follow-up visits depends on CKD stage, blood pressure, specific monitoring requirements (e.g.</s><s>associated with specific reno-protective therapy), complications and other clinical factors.</s><s>An annual follow-up for adults without renal failure and with controlled blood pressure has been recommended <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b51">52]</ref>.</s></p><p><s>Primary care physicians may see relatively few patients with ADPKD but should be alert to the impact that the condition can have throughout its course and to current approaches to treatment, monitoring and support.</s><s>Patients with suspected European ADPKD forum position statement ADPKD should be referred to a nephrologist, at least for a first visit, to establish the diagnosis, assess the rate of progression and the potential indication for specific reno-protective treatment, and to evaluate the presence of possible complications.</s><s>Re-referral procedures should be established according to clinical need and the evolving standards of good practice.</s></p><p><s>For example, nephrology re-referral has been recommended in the event of complications or if eGFR falls below 60 mL/min <ref type="bibr" target="#b51">[52]</ref>.</s><s>Patients should be clearly informed regarding the roles of the healthcare professionals and appropriate contact procedures and actions if they experience complications.</s><s>Special considerations for paediatric patients include the coordination of transitional care between paediatric and adult specialist nephrologists.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>E S R D</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dialysis and transplantation</head><p><s>Kidney transplantation is the optimal RRT modality <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b67">68]</ref>, resulting in excellent patient and graft survival, improved QoL and lower healthcare costs compared with dialysis <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b68">[69]</ref><ref type="bibr" target="#b69">[70]</ref><ref type="bibr" target="#b70">[71]</ref>.</s><s>Patients with ESRD due to ADPKD should be offered the opportunity to join a kidney transplant waiting list, if no contraindications exist.</s><s>Pre-emptive transplantation from a living donor gives the best outcomes <ref type="bibr" target="#b67">[68,</ref><ref type="bibr" target="#b71">72]</ref>, and this is facilitated in ADPKD by the relatively predictable decline in renal function.</s><s>Pre-transplant nephrectomy is not routinely performed, but may be appropriate in selected individuals <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b67">68]</ref>.</s><s>Patients with symptomatic massive polycystic liver disease may be evaluated for isolated liver transplant or combined liver and kidney transplant, depending on kidney function.</s><s>Importantly, even after a successful kidney transplant, patients require ongoing monitoring, care and support with respect to non-renal manifestations and complications.</s></p><p><s>Across Europe, fewer than 1 in 10 patients with ADPKD undergo kidney transplant as their first mode of RRT.</s><s>Around 7 out of 10 of these transplants come from living donors <ref type="bibr" target="#b1">[2]</ref>.</s><s>Rates of kidney transplantation overall, and living donation, vary considerably between countries.</s><s>In the Netherlands, 52% of all kidney transplants in 2015 came from living donors, while in some European countries this figure was &lt;10% <ref type="bibr" target="#b72">[73]</ref>.</s><s>The autosomal dominant nature of ADPKD necessitates screening of potential related donors to exclude the disease.</s><s>However, this need not be an obstacle to living donation: across Europe, the proportion of patients with ADPKD who receive a living donor kidney transplant as their first mode of RRT is more than twice as high as that in non-ADPKD CKD <ref type="bibr" target="#b1">[2]</ref>.</s><s>The main limitation is a shortage of available kidneys, while other barriers result from infrastructure, funding, legal frameworks, and attitudes among physicians and the public.</s><s>Collaborative efforts are needed to improve access to transplantation in line with EU initiatives.</s><s>In March 2016, the European Commission Working Group on Living Donation published a Toolbox to help Member States establish or optimize living donor programmes <ref type="bibr" target="#b73">[74]</ref>.</s></p><p><s>Haemodialysis and peritoneal dialysis are both suitable for most patients with ADPKD who cannot undergo a transplant or who are awaiting a transplant, and the choice between them should be made according to the individual circumstances <ref type="bibr" target="#b0">[1]</ref>.</s></p><p><s>Peritoneal dialysis is often not considered for use in patients with ADPKD owing to a lack of knowledge or experience of its use in this indication.</s><s>However, it can be an adequate mode of RRT in most ADPKD patients <ref type="bibr" target="#b74">[75]</ref><ref type="bibr" target="#b75">[76]</ref><ref type="bibr" target="#b76">[77]</ref>.</s><s>Nephrologists and patients should therefore be fully informed on the potential use, and limitations, of this modality in ADPKD.</s></p><p><s>Evidence suggests that there is room for improvement in the information on RRT options provided to patients with all forms of CKD, and in the involvement of patients in decision-making <ref type="bibr" target="#b77">[78,</ref><ref type="bibr" target="#b78">79]</ref>.</s><s>A European Commission-funded study, titled the 'Effect of Differing Kidney Disease Treatment Modalities and Organ Donation and Transplantation Practices on Health Expenditure and Patient Outcomes' (EDITH) pilot study is underway to assess the different treatment modalities for CKD in Europe and the factors influencing the treatment choices <ref type="bibr">[80]</ref>.</s><s>This study also aims to further develop and establish registries to follow-up living donors and transplant recipients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>R E S E A R C H</head><p><s>Further research is needed to improve our understanding of ADPKD and to improve patient outcomes <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b19">20]</ref>.</s><s>Patients should be informed of opportunities to join registries and clinical trials.</s><s>Paediatric patients with ADPKD should be included in research projects, as early disease detection and application of novel therapies at early disease stages might significantly improve the long-term outcome.</s></p><p><s>Local or national ADPKD registries provide valuable data, but these exist only in few European countries.</s><s>Further, international, multispecialist collaboration is necessary to address the challenges of ADPKD research <ref type="bibr" target="#b16">[17]</ref>.</s><s>The ERKNet and ERN RARE-LIVER are valuable developments in this regard.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>C A R E Q U A L I T Y C H E C K L I S T S</head><p><s>No widely accepted care quality standards exist for ADPKD, reflecting the lack of international evidence-based guidelines and pathways.</s><s>The KDIGO Conference recommended that consultation checklists are needed for both patients and physicians and that these should include the patient's experience of care and the impact of the disease, as well as the management of renal and extra-renal complications.</s><s>A Quality Improvement Tool, comprising checklists at each Route Map stage, is being developed in conjunction with patients to help them, and other stakeholders, assess care quality.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>C O N C L U S I O N S</head><p><s>While healthcare delivery is the responsibility of national governments and providers, European-level bodies have an important role in fostering greater harmony in the approach to ADPKD.</s><s>Individuals with ADPKD should have access to coordinated, patient-centred, multispecialist care according to the principles defined herein.</s><s>Collaboration between the various specialists involved in ADPKD care is encouraged to design and implement these services, and to work with patient organizations to promote awareness building, education and research.</s><s>All stakeholders, including national governments and healthcare providers, should support efforts to better inform patients and families and</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIGURE 1 :</head><label>1</label><figDesc><div><p><s>FIGURE 1: Schematic overview of key specialties involved in care for ADPKD showing examples of indications that may warrant referral subject to individual circumstances and local care organization.</s></p></div></figDesc><graphic coords="3,87.67,465.18,435.31,231.59" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIGURE 2 :</head><label>2</label><figDesc><div><p><s>FIGURE 2: Schematic illustration of a template patient Route Map for ADPKD care.</s></p></div></figDesc><graphic coords="4,90.45,490.07,449.57,224.11" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Information for patients, carers and families affected by autosomal dominant polycystic kidney disease (ADPKD)</s></p></div></figDesc><table><row><cell>Disease information</cell><cell>Explanation of the disease and its potential course and manifestations</cell></row><row><cell></cell><cell>Details of ADPKD patient organizations</cell></row><row><cell>Basic management and self-care</cell><cell>Self-management: water intake, low-salt diet, low-protein diet (where appropriate),</cell></row><row><cell></cell><cell>weight control, lifestyle (e.g. exercise), smoking cessation, caffeine intake</cell></row><row><cell></cell><cell>Cardiovascular risk management: importance, antihypertensive therapy, cholesterol-lowering therapy</cell></row><row><cell></cell><cell>Situations for contacting clinic (e.g. pain, complications)</cell></row><row><cell>Prognostic assessment</cell><cell>Rationale, interpretation and implications of prognostic risk score</cell></row><row><cell>Specific reno-protective pharmacotherapy</cell><cell>Indication, rationale/benefit, adverse effects, monitoring requirements</cell></row><row><cell></cell><cell>Clinical trial opportunities</cell></row><row><cell>Managing disease impact</cell><cell>Potential impact of the disease on activity (e.g. work and lifestyle)</cell></row><row><cell></cell><cell>Psychological impact and support available</cell></row><row><cell></cell><cell>Discussing ADPKD with employers</cell></row><row><cell></cell><cell>Issues regarding health insurance and mortgage applications</cell></row><row><cell></cell><cell>Family planning, including genetic counselling and pre-implantation genetic</cell></row><row><cell></cell><cell>diagnosis, contraception and pregnancy issues</cell></row><row><cell>Renal replacement therapy</cell><cell>Dialysis and transplantation options (according to clinical situation and availability)</cell></row><row><cell>Research</cell><cell>Registry entry, clinical trials, patient-reported outcome data collection</cell></row><row><cell>European ADPKD forum position statement</cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="570">T. Harris et al.</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>to empower them to act as fully informed and active partners in care, i.e. to maintain self-management approaches, deal with the impact of the condition, and participate in decision-making regarding healthcare policies, services and research.</s><s>The ADPKD Route Map, developed collaboratively by multidisciplinary ADPKD experts and patients, is a new tool to help patients navigate the services available to them and to help stakeholders and decision-makers take practical steps to ensure that all patients with ADPKD can access the comprehensive multispecialist care to which they are entitled.</s></p><p><s>The authors thank Dr Djalila Mekahli (Leuven, Belgium) for her review and comments on this article.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>F U N D I N G</head><p><s>The EAF was initiated by, and is currently solely supported by, Otsuka Pharmaceutical Europe Ltd.</s><s>The EAF Multispecialist Roundtable was co-sponsored by Otsuka Pharmaceutical Europe Ltd and Ipsen Farmaceutica BV.</s><s>No participants in the EAF initiative or in the Multispecialist Roundtable received fees in respect of these projects.</s><s>The EAF Report and this Multispecialist Position Paper contents are the opinions of the authors and do not necessarily represent those of the sponsors.</s><s>Editorial support in the development of this article was provided by Interel, London, UK, funded by Otsuka and Ipsen.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>C O N F L I C T O F I N T E R E S T S T A T E M E N T</head><p><s>EAF Faculty: T.H. reports non-financial support from Otsuka Pharmaceutical Europe Ltd, during the conduct of the study; non-financial support from Otsuka Pharmaceutical Europe Ltd, grants from Otsuka Pharmaceutical Europe Ltd, and personal fees from Otsuka Pharmaceutical UK Ltd, outside the submitted work.</s><s>R.S. reports personal fees from Otsuka, outside the submitted work.</s><s>B. De Coninck reports grants from Otsuka and from Ipsen, outside the submitted work.</s><s>O.D. reports grants from Otsuka, outside the submitted work.</s><s>J.P.H.D. has served as consultant for Gilead and Abbvie, and has been member of advisory boards of Gilead, BMS, Janssen and Abbvie.</s><s>The Radboudumc, on behalf of J.P.H.D., received honoraria or research grants from Novartis, Zambon, Ipsen, Otsuka, Falk, Merck, Janssen, AbbVie, and Norgine.</s><s>T.G. is a member of the Steering Committees of the TEMPO 3:4 (tolvaptan), REPRISE (tolvaptan) and DIPAK (lanreotide) studies, and received grants for research provided by Otsuka (manufacturer of tolvaptan) and Ipsen (manufacturer of lanreotide).</s><s>All fees are paid to his employer.</s><s>J.L.G. reports personal fees from Otsuka, during the conduct of the study.</s><s>A.C.M.O.</s><s>reports personal fees and other from Otsuka, outside the submitted work.</s><s>Y.P. reports personal fees from Cliniques universitaires St Luc, outside the submitted work.</s><s>V.T. reports grant, non-financial support and other from Otsuka during the conduct of the study; grants from Otsuka, non-financial support and other from Vertex, grant from Palladio, and personal fees from UptoDate, outside the submitted work.</s><s>T.E. and A.K. declare no conflict of interest.</s></p><p><s>Multispecialist participants K.B. reports grants and personal fees from Novartis, and grants and personal fees from Otsuka, during the conduct of the study.</s><s>D.P. reports grants from Ipsen, personal fees and non-financial support from Otsuka, outside the submitted work.</s><s>D.C., L.D., M.E., E.L., H.V.P. and R.V. declare no conflict of interest.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>R E F E R E N C E S</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Autosomal dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Devuyst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">U</forename><surname>Eckardt</surname></persName>
		</author>
		<ptr target="http://www.kidney-international.com/cms/attachment/2043453066/2056082832/mmc1.pdf" />
	</analytic>
	<monogr>
		<title level="m">Improving Global Outcomes (KDIGO) Controversies Conference</title>
				<imprint>
			<date type="published" when="2015">15 November 2017. 2015</date>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="17" to="27" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Spithoven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kramer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Meijer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="1244" to="1252" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival-an analysis of data from the ERA-EDTA Registry</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Spithoven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kramer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Meijer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="15" to="25" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Liver involvement in early autosomal-dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Abebe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Torres</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="155" to="164" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>e6</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Vascular complications in autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Perrone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Malek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Watnick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Nephrol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="589" to="598" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">I</forename><surname>Helal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Reed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mettler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Nephrol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="362" to="370" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD Stages 1-4: a cross-sectional study</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Miskulin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Z</forename><surname>Abebe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Chapman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="214" to="126" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Quality of life of patients with ADPKD-Toranomon PKD QOL study: cross-sectional study</title>
		<author>
			<persName><forename type="first">T</forename><surname>Suwabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ubara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mise</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Nephrol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">179</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Understanding the physical and emotional impact of early-stage ADPKD: experiences and perspectives of patients and physicians</title>
		<author>
			<persName><forename type="first">A</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Marsh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Kidney J</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="531" to="537" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Simms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Thong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Dworschak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1130" to="1140" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">The effect of disease severity markers on quality of life in autosomal dominant polycystic kidneydisease: a systematic review, meta-analysis and meta-regression</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Neijenhuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Kievit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Perrone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Nephrol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">169</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Autosomal polycystic kidney disease in children</title>
		<author>
			<persName><forename type="first">S</forename><surname>Polubothu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kerecuk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">253</biblScope>
			<biblScope unit="page">2957</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">The spectrum of autosomal dominant polycystic kidney disease in children and adolescents</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">V</forename><surname>Reddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Chapman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Nephrol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="31" to="42" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Spanish guidelines for the management of autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">E</forename><surname>Ars</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bernis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fraga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="95" to="105" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">KHA-CARI autosomal dominant polycystic kidney disease guidelines</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Rangan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Savige</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Nephrol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="521" to="622" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Gansevoort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Arici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Benzing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="337" to="348" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title level="m" type="main">Translating Science into Policy to Improve ADPKD Care in Europe</title>
		<author>
			<persName><forename type="first">Adpkd</forename><surname>European</surname></persName>
		</author>
		<author>
			<persName><surname>Forum</surname></persName>
		</author>
		<ptr target="EAF,2015.www.pkdinternational.org/EAF_ADPKD_Policy_Report_2015" />
		<imprint>
			<date type="published" when="2017-11-15">15 November 2017</date>
		</imprint>
	</monogr>
	<note>date last accessed</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">More than a kidney disease: a patientcentred approach to improving care in autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">S</forename><surname>Youssouf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>'donoghue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="693" to="695" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>European ADPKD forum position statement 18</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">ADPKD diagnosis in Europe: patient reports of symptoms at recognition and post diagnosis support</title>
		<author>
			<persName><forename type="first">B</forename><surname>De Coninck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Galletti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Makin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="86" to="87" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Identifying and integrating consumer perspectives in clinical practice guidelines on autosomaldominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Tunnicliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lopez-Vargas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrology (Carlton)</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="122" to="132" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Lantinga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Casteleijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Geudens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="144" to="150" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">International multi-specialty Delphi survey: Identification of diagnostic criteria for hepatic and renal cyst infection</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Lantinga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Darding</surname></persName>
		</author>
		<author>
			<persName><surname>De Se ´vaux</surname></persName>
		</author>
		<author>
			<persName><surname>Rg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephron</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="205" to="214" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Healthcare resource consumption and cost of care among patients with polycystic kidney disease in Italy</title>
		<author>
			<persName><forename type="first">Degli</forename><surname>Esposti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Veronesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Perrone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinicoecon Outcomes Res</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="233" to="239" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Real-world costs of autosomal dominant polycystic kidney disease in the Nordics</title>
		<author>
			<persName><forename type="first">D</forename><surname>Eriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Eklund</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Health Services Research</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">560</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title level="m" type="main">European Rare Kidney Disease Reference Network Website</title>
		<ptr target="https://www.erknet.org" />
		<imprint>
			<date type="published" when="2017-11-15">15 November 2017</date>
		</imprint>
	</monogr>
	<note>date last accessed</note>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<ptr target="http://www.rare-liver.eu" />
		<title level="m">European Reference Network on Hepatological Diseases Website</title>
				<imprint>
			<date type="published" when="2017-11-15">15 November 2017</date>
		</imprint>
	</monogr>
	<note>date last accessed</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Patients&apos; continuing use of an online health record: a quantitative evaluation of 14, 000 patient years of access data</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Phelps</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Simpson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">e241</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Barriers to patient participation in a selfmanagement and education website Renal PatientView: A questionnairebased study of inactive users</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Hazara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhandari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Med Inform</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="10" to="14" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<ptr target="http://www.arthritisresearchuk.org/arthritis-information/inflammatory-arthritis-pathway.aspx" />
		<title level="m">Arthritis Research UK. The inflammatory arthritis pathway</title>
				<imprint>
			<date type="published" when="2017-11-15">15 November 2017</date>
		</imprint>
	</monogr>
	<note>date last accessed</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Adult polycystic kidney disease patients show a very similar cardiovascular comorbidity profile to CKD patients with other etiologies. Most cardiovascular and renal risk factors are not controlled in the majority of patients (Abs SA-PO558)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Go ´rriz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Montomoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Castro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">764A</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Marlais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Cuthell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Langan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dis Child</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="1142" to="1147" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group</title>
		<author>
			<persName><forename type="first">S</forename><surname>Klahr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Breyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Beck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="2037" to="2047" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">KHA-CARI autosomal dominant polycystic kidney disease guideline: diet and lifestyle management</title>
		<author>
			<persName><forename type="first">K</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Rangan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lopez-Vargas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Nephrol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="572" to="581" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease</title>
		<author>
			<persName><forename type="first">Kidney</forename><surname>Disease</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="1" to="150" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Dietary interventions for adults with chronic kidney disease</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Maggo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Campbell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">D011998</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Blood pressure in early autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Schrier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Z</forename><surname>Abebe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Perrone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="2255" to="2266" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Biliary tract and liver complications in polycystic kidney disease</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Judge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chs</forename><surname>Harper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Storey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2738" to="2748" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Wijnands</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Neijenhuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Kievit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Int</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1578" to="1583" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Development and validation of a disease-specific questionnaire to assess patient-reported symptoms in polycystic liver disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Neijenhuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Gevers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hogan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="151" to="160" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
		<title level="m" type="main">The association of combined total kidney and liver volume with gastrointestinal symptoms and pain in patients with later stage ADPKD</title>
		<author>
			<persName><forename type="first">Hma</forename><surname>D'agnolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Casteleijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>De Fijter</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Abstract SP018]</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="90" to="99" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: management of polycystic liver disease</title>
		<author>
			<persName><forename type="first">J</forename><surname>Savige</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mallett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Tunnicliffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Nephrol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="618" to="622" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>e5</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">R</forename><surname>Sherstha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mckinley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Russ</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1282" to="1286" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Intracranial aneurysms in patients with autosomal dominant polycystic kidney disease: prevalence, risk of rupture, and management. A systematic review</title>
		<author>
			<persName><forename type="first">F</forename><surname>Cagnazzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gambacciani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Morganti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neurochir (Wien)</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="811" to="821" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Vlak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Algra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Brandenburg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="626" to="636" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: management of intracranial aneurysms</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Dexter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Nephrol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="612" to="617" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>e20</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">A painful inheritance-patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Rangan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ruospo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="790" to="800" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Novel treatment protocol for ameliorating refractory, chronic pain in patients with autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Casteleijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Van Gastel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Blankestijn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="972" to="981" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: psychosocial care</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mallett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lopez-Vargas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Nephrol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="590" to="594" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>e5</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Health-related quality of life (HrQoL) measures in autosomal dominant polycystic kidney disease (ADPKD)</title>
		<author>
			<persName><forename type="first">D</forename><surname>Oberdhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Krasa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schaefer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Value Health</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">A512</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<author>
			<persName><surname>Uk Renal Registry</surname></persName>
		</author>
		<ptr target="https://www.thinkkidneys.nhs.uk/ckd/workstreams/measurement-workstream/" />
		<title level="m">Think Kidneys: Measurement Workstream</title>
				<imprint>
			<date type="published" when="2017-11-17">17 November 2017</date>
		</imprint>
	</monogr>
	<note>date last accessed</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Autosomal dominant polycystic kidney disease: the changing face of clinical management</title>
		<author>
			<persName><forename type="first">Acm</forename><surname>Ong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Devuyst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Knebelmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">385</biblScope>
			<biblScope unit="page" from="1913" to="2002" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Bost</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Torres</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="479" to="486" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Automated segmentation of kidneys from MR images in patients with autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="576" to="584" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Kline</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Korfiatis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Edwards</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="241" to="248" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Estimation of total kidney volume in autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Spithoven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Van Gastel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Messchendorp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="792" to="801" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Irazabal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Rangel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Bergstralh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="160" to="172" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">The PROPKD Score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">Cornec-Le</forename><surname>Gall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Audre</forename><surname>´zet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Rousseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="942" to="951" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial</title>
		<author>
			<persName><forename type="first">O</forename><surname>Devuyst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Gansevoort</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1592" to="1602" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<monogr>
		<title level="m" type="main">European Commission Expert Group on Rare Diseases. Recommendation on Cross Border Genetic Testing of Rare Diseases in the European Union</title>
		<ptr target="http://ec.europa.eu/health/rare_diseases/docs/2015_recommendation_crossbordergenetictesting_en.pdf" />
		<imprint>
			<date type="published" when="2015-11-15">November 2015. 15 November 2017</date>
		</imprint>
	</monogr>
	<note>date last accessed</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">An efficient and comprehensive strategy for genetic diagnostics of polycystic kidney disease</title>
		<author>
			<persName><forename type="first">T</forename><surname>Eisenberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Decker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hiersche</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0116680</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">T</forename><surname>Harris</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<monogr>
		<title level="m" type="main">Attitudes towards prenatal diagnosis and preimplantation genetic diagnosis in patients with autosomal dominant polycystic kidney disease. Oral presentation 039 at the British Renal Society/ Renal Association Conference</title>
		<author>
			<persName><forename type="first">O</forename><surname>Swift</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Babman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Side</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014-05-02">29 April-2 May 2014</date>
			<pubPlace>Glasgow, UK</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy</title>
		<author>
			<persName><forename type="first">J</forename><surname>Harper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Geraedts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Borry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Reprod</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1603" to="1609" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<monogr>
		<title level="m" type="main">Tolvaptan for ADPKD: Interpreting the NICE Decision</title>
		<ptr target="https://renal.org/wp-content/uploads/2017/06/tolvaptan-in-adpkd-nice-commentary.pdf" />
		<imprint>
			<date type="published" when="2016-11-15">2016. 15 November 2017</date>
		</imprint>
		<respStmt>
			<orgName>Renal Association Working Group on Tolvaptan</orgName>
		</respStmt>
	</monogr>
	<note>date last accessed</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Mao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Ong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">F1000Res</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">2029</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Clinical pattern of tolvaptanassociated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Watkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kaplowitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Saf</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1103" to="1113" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Renal transplantation in autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">N</forename><surname>Kanaan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Devuyst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Pirson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Nephrol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="455" to="465" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Pirson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Christophe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Goffin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="24" to="28" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Jacquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pallet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kessler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Int</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="582" to="587" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Renal transplant in patients with polycystic disease: the Italian experience</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mosconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Persici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Cuna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplant Proc</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="2635" to="2640" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes Working Group and ERBP</title>
		<author>
			<persName><forename type="first">D</forename><surname>Abramowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hazzan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Maggiore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="691" to="697" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">European Directorate for the Quality of Medicines &amp; HealthCare of the Council of Europe (EDQM) and Organizacio ´n Nacional de Trasplantes</title>
		<ptr target="https://www.edqm.eu/sites/default/files/newsletter_transplant_volume_21_september_2016.pdf" />
	</analytic>
	<monogr>
		<title level="j">Newsletter Transplant. International Figures on Donation and Transplantation</title>
		<imprint>
			<date type="published" when="2015-11-15">2015. 15 November 2017</date>
		</imprint>
	</monogr>
	<note>date last accessed</note>
</biblStruct>

<biblStruct xml:id="b73">
	<monogr>
		<title level="m" type="main">European Commission Working Group on Living Donation</title>
		<ptr target="https://www.edqm.eu/sites/default/files/newsletter_transplant_volume_21_september_2016.pdf" />
		<imprint>
			<date type="published" when="2016-03-15">March 2016. 15 November 2017</date>
		</imprint>
	</monogr>
	<note>Toolbox Living Kidney Donation. date last accessed</note>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Long-term outcome of patients with autosomal dominant polycystic kidney diseases receiving peritoneal dialysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Raftery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="946" to="951" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Peritoneal dialysis as the first-line renal replacement therapy in patients with autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Szeto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Kwan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="903" to="907" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Peritoneal dialysis can be an option for dominant polycystic kidney disease: an observational study</title>
		<author>
			<persName><forename type="first">D</forename><surname>Janeiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Portole ´s</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Tato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Perit Dial Int</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="530" to="536" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Patients&apos; perceptions of information and education for renal replacement therapy: an independent survey by the European Kidney Patients&apos; Federation on information and support on renal replacement therapy</title>
		<author>
			<persName><forename type="first">W</forename><surname>Van Biesen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Van Der Veer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Murphey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e103914</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Patient perspectives on the choice of dialysis modality: results from the empowering patients on choices for renal replacement therapy (EPOCH-RRT) Study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Dahlerus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Quinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Messersmith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="901" to="910" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">European ADPKD forum position statement</title>
		<imprint/>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
